- This event has passed.
Accelerating BioVenture Innovation Kick-Off
August 29 @ 5:30 pm - 8:30 pm
We formally invite you to join Weill Cornell Medicine and the greater NYC life science startup community for the kick-off of our Accelerating BioVenture Innovation accelerator with special guest – Erandi De Silva, PhD, Co-Founder & Senior Vice President of Product Development at Forge Biologics! Dr. De Silva was selected by Fierce Pharma as one of its 2022 Fiercest Women in Life Sciences. We are excited to have her on campus to share her personal story and startup journey.
The event is scheduled for Tuesday, August 29, 5:30-8:30pm. It will take place in-person at Uris Auditorium, 1300 York Avenue @ 69th Street, and will be followed by a networking reception with cocktails in Griffis Faculty Lounge (same location). This is a great opportunity to meet like-minded faculty, trainees and clinicians interested in translational science and medicine.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. Investors include Drive Capital, Perceptive Xontogeny Venture Fund, RA Capital Management, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and Aisling Capital. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
About Accelerating BioVenture Innovation
ABI is a training program for life science postdocs/trainees, PhD students, and medical school students. The 15-week program builds teams around patented technologies from Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University. Teams develop business plans in the form of an investor pitch around these technologies. The teams are matched with MBA students and biotech industry professionals to broaden their business acumen and promote collaboration. Weekly lectures cover various startup fundamentals. At the end of the course, the teams compete in a final pitch event with institutional VCs and angel investors as judges. If you are interested in participating in this Fall course, please register here.